| Market Cap | 6.1B |
| Market Cap (USD) | $844.6M |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | 0.26 |
| Dividend Yield | - |
| D/E Ratio | 0.12 |
| Current Ratio | 5.66 |
| Market Segment | SME |
| Currency | CNY |
Business Overview
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | C27医药制造业 |
| Market Segment | SME |
| Currency | CNY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | 精华制药 |
| Ticker | 002349 |
| Exchange | SZSE |
| Sector | 证监会行业分类 |
| Industry | C27医药制造业 |
| Market Segment | SME |
| Fiscal Year | 2024 |
| Currency | CNY |
| Market Cap | 6.1B |
| Market Cap (USD) | $844.6M |
| Revenue | 1.4B |
| Net Income | 247.0M |
| P/E Ratio | - |
| EPS | 0.26 |
| Net Margin | 17.6% |
| ROE | 8.4% |
| Dividend Yield | - |
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.